Update on triple-negative breast cancer: prognosis and management strategies

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results (SEER)Lifetime risk of developing or dying of cancer [webpage on the Internet]Bethesda, MDSurveillance Research Program nd. Available from: http://seer.cancer.gov/statistics/types/lifetimerisk.html. Accessed May 15, 2012.
   Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASGelberRDThürlimannBSennHJPanel membersStrategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• LayfieldLJGuptaDMooneyEEAssessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methodsBreast J20006318919611348363
   PubMedGoogle Scholar
• PuttiTCPinderSEElstonCWLeeAHEllisIOBreast pathology practice: most common problems in a consultation serviceHistopathology200547544545716241992
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJWaleCHowellTHoughtonJBaumMRetrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyJ Clin Oncol200523307512751716234518
   PubMed Web of Science ®Google Scholar
• RegitnigPReinerADingesHPQuality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratoriesVirchows Arch2002441432833412404057
   PubMed Web of Science ®Google Scholar
• EiermannWPaepkeSAppfelstaedtJLetrozole Neo-Adjuvant Breast Cancer Study GroupLetrozole neo-adjuvant breast cancer study group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter studyAnn Oncol200112111527153211822750
   PubMed Web of Science ®Google Scholar
• StendahlMRydénLNordenskjöldBJönssonPELandbergGJirströmKHigh progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patientsClin Cancer Res200612154614461816899609
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFWolffACManguPBTeminSAmerican society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Oncol Pract20106419519721037871
   PubMed Web of Science ®Google Scholar
• McCulloughAEDell’OrtoPReinholzMMConcordance of HER2 central assessment by two international central laboratories: a ring study within the framework of the adjuvant HER2-positive ALTTO trial (BIG2-06/N063D/EGF106708)Cancer Res201070Suppl abst P3-10-36.
   Google Scholar
• AllredDCIssues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancerMod Pathol201023Suppl 2S52S5920436503
   PubMed Web of Science ®Google Scholar
• NagleRBBöckerWDavisJRCharacterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cellsJ Histochem Cytochem19863478698812423579
   PubMed Web of Science ®Google Scholar
• DairkeeSHPuettLHackettAJExpression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissueJ Natl Cancer Inst19888096916952453676
   PubMedGoogle Scholar
• PintensSNevenPDrijkoningenMTriple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1J Clin Pathol200962762462819561231
   PubMed Web of Science ®Google Scholar
• CioccaDRGagoFEFanelliMACalderwoodSKCo-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implicationsJ Steroid Biochem Mol Biol20061021–5324017049840
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMLivasyCARace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA2006295212492250216757721
   PubMed Web of Science ®Google Scholar
• NielsenTOHsuFDJensenKImmunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaClin Cancer Res2004105367537415328174
   PubMed Web of Science ®Google Scholar
• CuzickJDowsettMWaleCPrognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score – results from TransATACCancer Res200969Suppl 24 abst 74.
   Web of Science ®Google Scholar
• RakhaEAElsheikhSEAleskandaranyMATriple-negative breast cancer: distinguishing between basal and nonbasal subtypesClin Cancer Res2009152302231019318481
   PubMed Web of Science ®Google Scholar
• KreikeBvan KouwenhoveMHorlingsHGene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast Cancer Res20079R6517910759
   PubMed Web of Science ®Google Scholar
• RakhaEAEl-SayedMEGreenARLeeAHRobertsonJFEllisIOPrognostic markers in triple negative breast cancerCancer2007109253217146782
   PubMed Web of Science ®Google Scholar
• CheangMCVoducDBajdikCBasal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeClin Cancer Res2008141368137618316557
   PubMed Web of Science ®Google Scholar
• SasaMBandoYTakahashiMHiroseTNagaoTScreening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancerJ Surg Oncol200897303417929254
   PubMed Web of Science ®Google Scholar
• DabbsDJChivukulaMCarterGBhargavaRBasal phenotype of ductal carcinoma in situ: recognition and immunohistologic profileMod Pathol2006191506151116941011
   PubMed Web of Science ®Google Scholar
• PerouCMMolecular stratification of triple-negative breast cancersOncologist201015Suppl 5394821138954
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol2009271160116719204204
   PubMed Web of Science ®Google Scholar
• BertucciFFinettiPCerveraNHow basal are triple-negative breast cancers?Int J Cancer200812323624018398844
   PubMed Web of Science ®Google Scholar
• de RondeJJHannemannJHalfwerkHConcordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy responseBreast Cancer Res Treat201011911912619669409
   PubMed Web of Science ®Google Scholar
• LehmanBDBauerJAChenXTranscriptome analysis of triple negative breast cancers identifies six distinct biological subgroups and reveals therapeutic strategiesCancer Res20107024s Suppl abst PD01-07.
   Web of Science ®Google Scholar
• BauerKRBrownMCressRDPariseCACaggianoVDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer RegistryCancer200710991721172817387718
   PubMed Web of Science ®Google Scholar
• MorrisGJNaiduSTophamAKDifferences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results databaseCancer200711087688417620276
   PubMed Web of Science ®Google Scholar
• SteadLALashTLSobierajJETriple negative breast cancers are increased in black women regardless of age or body mass indexBreast Cancer Res2009112R1819320967
   PubMed Web of Science ®Google Scholar
• LundMJTriversKFPorterPLRace and triple negative threats to breast cancer survival: A population-based study in Atlanta, GABreast Cancer Res Treat200911335737018324472
   PubMed Web of Science ®Google Scholar
• MillikanRCNewmanBTseCKEpidemiology of basal-like breast cancerBreast Cancer Res Treat2008109112313917578664
   PubMed Web of Science ®Google Scholar
• FoulkesWDStefanssonIMChappuisPOGermline BRCA1 mutations and a basal epithelial phenotype in breast cancerJ Natl Cancer Inst2003951482148514519755
   PubMed Web of Science ®Google Scholar
• EvansDGHowellAAre we ready for online tools in decision making for BRCA1/2 mutation carriers?J Clin Oncol201230547147322231044
   PubMed Web of Science ®Google Scholar
• AntoniouACBeesleyJMcGuffogLCIMBACommon breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk predictionCancer Res2010709742975421118973
   PubMed Web of Science ®Google Scholar
• RakhaEAReis-FilhoJSEllisIOBasal-like breast cancer: a critical reviewJ Clin Oncol2008262568258118487574
   PubMed Web of Science ®Google Scholar
• Reis-FilhoJSTuttAJTriple negative tumours: a critical reviewHistopathology20085210811818171422
   PubMed Web of Science ®Google Scholar
• ArmesJEVenterDJThe pathology of inherited breast cancerPathology200234430931412190286
   PubMed Web of Science ®Google Scholar
• FulfordLGEastonDFReis-FilhoJSSpecific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of the breastHistopathology200649223416842243
   PubMed Web of Science ®Google Scholar
• YoungSPilarskiRDonenburgTThe prevalence of BRCA mutations among young women with triple-negative breast cancerBMC Cancer200998619298662
   PubMed Web of Science ®Google Scholar
• KwonJSGutierrez-BarreraAMYoungDExpanding the criteria for BRCA mutation testing in breast cancer survivorsJ Clin Oncol2010284214422020733129
   PubMed Web of Science ®Google Scholar
• FutrealPALiuQShattuck-EidensDBRCA1 mutations in primary breast and ovarian carcinomasScience19942661201227939630
   PubMed Web of Science ®Google Scholar
• LancasterJMCochranCJBrownleeHADetection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation testJ Natl Cancer Inst1996885525548606385
   PubMedGoogle Scholar
• EstellerMSparksAToyotaMAnalysis of adenomatous polyposis coli promoter hypermethylation in human cancerCancer Res2000604366437110969779
   PubMed Web of Science ®Google Scholar
• BaldwinRLNemethETranHBRCA1 promoter region hyper-methylation in ovarian carcinoma: a population-based studyCancer Res2000605329533311034065
   PubMed Web of Science ®Google Scholar
• GrushkoTANwachukwuNCharoenthammaraksaSEvaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancersJ Clin Oncol201028Suppl abst 10510.
   Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer2004481481915510162
   PubMed Web of Science ®Google Scholar
• TurnerNCReis-FilhoJSRussellAMBRCA1 dysfunction in sporadic basal-like breast cancerOncogene2007142126213217016441
   PubMed Web of Science ®Google Scholar
• PhippsAMaloneKPorterPDalingJRLiCIReproductive and hormonal risk factors for postmenopausal luminal, Her-2-overexpressing, and triple-negative breast cancerCancer20081131521152618726992
   PubMed Web of Science ®Google Scholar
• YangXShermanMRimmDDifferences in risk factors for breast cancer molecular subtypes in a population-based studyCancer Epidemiol Biomarkers Prev20071643944317372238
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res2007134429443417671126
   PubMed Web of Science ®Google Scholar
• CollettKStefanssonIMEideJA basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumorsCancer Epidemiol Biomarkers Prev2005141108111215894660
   PubMed Web of Science ®Google Scholar
• YangWTDrydenMBroglioKMammographic features of triple receptor-negative primary breast cancers in young premenopausal womenBreast Cancer Res Treat200811140541018026834
   PubMed Web of Science ®Google Scholar
• WangYIkedaDMNarasimhanBEstrogen receptor negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpressionRadiology200824636737518180338
   PubMed Web of Science ®Google Scholar
• KimSHSeoBKLeeJCorrelation of ultrasound findings with histology, tumor grade, and biological markers in breast cancerActa Oncol2008471531153818607848
   PubMed Web of Science ®Google Scholar
• BasuSChenWTchouJComparison of triple negative and estrogen receptor-positive/progesterone receptorpositive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorode-oxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterizationCancer2008112995100018098228
   PubMed Web of Science ®Google Scholar
• ThikeAACheokPYJara-LazaroARTanBTanPTanPHTriple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancerMod Pathol20102312313319855377
   PubMed Web of Science ®Google Scholar
• TognonCKnezevichSRHuntsmanDExpression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinomaCancer Cell20022536737612450792
   PubMed Web of Science ®Google Scholar
• PerssonMAndrénYMarkJHorlingsHMPerssonFStenmanGRecurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neckProc Natl Acad Sci U S A200910644187401874419841262
   PubMed Web of Science ®Google Scholar
• AzoulaySLaéMFréneauxPKIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcomeMod Pathol2005181623163116258515
   PubMed Web of Science ®Google Scholar
• FourquetAVilcoqJRZafraniBSchliengerPJullienDCampanaFMedullary breast carcinoma: the role of radiotherapy as primary treatmentRadiother Oncol198710163671767
   PubMed Web of Science ®Google Scholar
• DendaleRVincent-SalomonAMouret-FourmeEMedullary breast carcinoma: prognostic implications of p53 expressionInt J Biol Markers2003189910512841678
   PubMed Web of Science ®Google Scholar
• HuoberJBGelberSThurlimannBPrognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trialsJ Clin Oncol201028Suppl abst 630.
   Google Scholar
• HennessyBTGiordanoSBroglioKBiphasic metaplastic sarcomatoid carcinoma of the breastAnn Oncol20061760561316469754
   PubMed Web of Science ®Google Scholar
• PiccartMVialeGEllisPAbramowiczMCareyLTips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?Ecancermedicalscience2011521722276059
   PubMedGoogle Scholar
• KusinskaRPotemskiPJesionek-KupnickaDKordekRImmunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma relation with grade, stage, estrogen receptor and HER2Pol J Pathol20055610711016334976
   PubMedGoogle Scholar
• CrabbSJCheangMCLeungSBasal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancerClin Breast Cancer2008824925618650155
   PubMed Web of Science ®Google Scholar
• TanDSMarchióCJonesRLTriple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patientsBreast Cancer Res Treat2008111274417922188
   PubMed Web of Science ®Google Scholar
• FoulkesWDMetcalfeKHannaWDisruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinomaCancer2003981569157714534871
   PubMed Web of Science ®Google Scholar
• JatoiIAndersonWFJeongJHRedmondCKBreast cancer adjuvant therapy: time to consider its time-dependent effectsJ Clin Oncol201129172301230421555693
   PubMed Web of Science ®Google Scholar
• KenneckeHYerushalmiRWoodsRMetastatic behavior of breast cancer subtypesJ Clin Oncol201028203271327720498394
   PubMed Web of Science ®Google Scholar
• FreedmanGAndersonPLiTNicolaouNLocoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiationCancer200911594695119156929
   PubMed Web of Science ®Google Scholar
• VoducKDCheangMCTyldesleySGelmonKNielsenTOKenneckeHBreast cancer subtypes and the risk of local and regional relapseJ Clin Oncol201028101684169120194857
   PubMed Web of Science ®Google Scholar
• LoweryAJKellMRGlynnRWKerinMJSweeneyKJLocoregional recurrence after breast cancer surgery: a systematic review by receptor phenotypeBreast Cancer Res Treat2012133383184122147079
   PubMed Web of Science ®Google Scholar
• MontagnaEBagnardiVRotmenszNBreast cancer subtypes and outcome after local and regional relapseAnn Oncol201223232433121525402
   PubMed Web of Science ®Google Scholar
• LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol2008261275128118250347
   PubMed Web of Science ®Google Scholar
• SmidMWangYZhangYSubtypes of breast cancer show preferential site of relapseCancer Res2008683108311418451135
   PubMed Web of Science ®Google Scholar
• LinNUBellonJRWinerEPCNS metastases in breast cancerJ Clin Oncol200422173608361715337811
   PubMed Web of Science ®Google Scholar
• HeitzFHarterPTrautACerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumorsJ Clin Oncol200826Suppl abst 1010.
   Google Scholar
• DawoodSBroglioKEstevaFJSurvival among women with triple receptor-negative breast cancer and brain metastasesAnn Oncol20092062162719150943
   PubMed Web of Science ®Google Scholar
• DesmedtCHaibe-KainsBWirapatiPBiological processes associated with breast cancer clinical outcome depend on the molecular subtypesClin Cancer Res2008145158516518698033
   PubMed Web of Science ®Google Scholar
• KeamBImSALeeKHKi-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBreast Cancer Res2011132R2221366896
   PubMed Web of Science ®Google Scholar
• AleskandaranyMAGreenARBenhasounaAAPrognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerBreast Cancer Res2012141R322225836
   PubMed Web of Science ®Google Scholar
• CancelloGMaisonneuvePRotmenszNPrognosis in women with small (T1 mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypesBreast Cancer Res Treat2011127371372021452022
   PubMed Web of Science ®Google Scholar
• AlbergariaARicardoSMilaneziFNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?BMC Cancer20111129921762477
   PubMed Web of Science ®Google Scholar
• TangDXuSZhangQZhaoWThe expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancerMed Oncol201229252653321519872
   PubMed Web of Science ®Google Scholar
• KashiwagiSYashiroMTakashimaTSignificance of E-cadherin expression in triple-negative breast cancerBr J Cancer2010103224925520551954
   PubMed Web of Science ®Google Scholar
• VialeGRotmenszNMaisonneuvePInvasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivityBreast Cancer Res Treat2009116231732818839307
   PubMed Web of Science ®Google Scholar
• MohammedRAEllisIOMahmmodAMLymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significanceMod Pathol201124677478521378756
   PubMed Web of Science ®Google Scholar
• PratAParkerJSKarginovaOPhenotypic and molecular characterization of the claudinlow intrinsic subtype of breast cancerBreast Cancer Res201012R6820813035
   PubMed Web of Science ®Google Scholar
• OnoMTsudaHShimizuCTumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Res Treat2012132379380521562709
   PubMed Web of Science ®Google Scholar
• DesmedtCDi LeoAde AzambujaEMultifactorial approach to predicting resistance to anthracyclinesJ Clin Oncol2011291578158621422418
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMBlohmerJUDefinition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesJ Clin Oncol201230151796180422508812
   PubMed Web of Science ®Google Scholar
• RouzierRPerouCMSymmansWFBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res200511165678568516115903
   PubMed Web of Science ®Google Scholar
• CareyLADeesECSawyerLThe triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res20071382329233417438091
   PubMed Web of Science ®Google Scholar
• StraverMEGlasAMHannemannJThe 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Res Treat2010119355155819214742
   PubMed Web of Science ®Google Scholar
• SchottAFHayesDFDefining the benefits of neoadjuvant chemotherapy for breast cancerJ Clin Oncol201230151747174922508810
   PubMed Web of Science ®Google Scholar
• Metzger-FilhoOTuttAde AzambujaEDissecting the heterogeneity of triple-negative breast cancerJ Clin Oncol201230151879188722454417
   PubMed Web of Science ®Google Scholar
• Di LeoADesmedtCBartlettJMFinal results of a meta-analysis testing HER2 and topoisomerase II alpha genes as predictors of incremental benefit from anthracyclines in breast cancerJ Clin Oncol20102872s Suppl abst 519.
   Web of Science ®Google Scholar
• RoccaAParadisoASismondiPBenefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancerJ Clin Oncol20112987s Suppl abst 1031.
   Web of Science ®Google Scholar
• De LaurentiisMCancelloGD’AgostinoDTaxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trialsJ Clin Oncol2008261445318165639
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesCGodwinJComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• IsakoffSJTriple-negative breast cancer: role of specific chemotherapy agentsCancer J201016536120164691
   PubMed Web of Science ®Google Scholar
• GronwaldJByrskiTHuzarskiTNeoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsJ Clin Oncol2009277s Suppl abst 502.
   Google Scholar
• ByrskiTHuzarskiTDentRResponse to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Res Treat200911535936318649131
   PubMed Web of Science ®Google Scholar
• ByrskiTGronwaldJHuzarskiTPathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapyJ Clin Oncol20102837537920008645
   PubMed Web of Science ®Google Scholar
• AlbaEChaconJLluchAChemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006–2003-A multicenter, randomized phase II studyJ Clin Oncol20112983s Suppl abst 1015.
   Web of Science ®Google Scholar
• AmirEMillerNGeddieWProspective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancerJ Clin Oncol201230658759222124102
   PubMed Web of Science ®Google Scholar
• ForastiereAAHakesTBWittesJTWittesRECisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedulesAm J Clin Oncol1982532432477044098
   PubMed Web of Science ®Google Scholar
• SledgeGWJrLoehrerPJSrRothBJEinhornLHCisplatin as first-line therapy for metastatic breast cancerJ Clin Oncol1988612181118143199166
   PubMed Web of Science ®Google Scholar
• O’BrienMETalbotDCSmithIECarboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose scheduleJ Clin Oncol19931111211221178229125
   PubMed Web of Science ®Google Scholar
• AlbainKSNagSMCalderillo-RuizGGemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatmentJ Clin Oncol200826243950395718711184
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol200220122812282312065558
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200725335210521717968020
   PubMed Web of Science ®Google Scholar
• PerezEAPatelTMoreno-AspitiaAEfficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancerBreast Cancer Res Treat2010121226127120229176
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med20073572666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol2010283239324720498403
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJABrufskyAMRiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancerClin Breast Cancer2008837037318757267
   PubMed Web of Science ®Google Scholar
• FDA pulls approval for avastin in breast cancerCancer Discov201117OF1OF2 Epub November 23, 2011.
   Web of Science ®Google Scholar
• RyanPDTungNMIsakoffMNeoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacyJ Clin Oncol20092715s Suppl abst 551.
   Web of Science ®Google Scholar
• GerberBEidtmannHRezaiMNeoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44)J Clin Oncol20112981s abst 1006.
   Web of Science ®Google Scholar
• BearHDTangGRastogiPThe effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40J Clin Oncol201129 abst LBA 1005.
   Google Scholar
• Hoffmann-La RocheBEATRICE Study: a study of avastin (bevacizumab) adjuvant therapy in triple negative breast cancerClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 15, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00528567. Accessed May 15, 2012.
   Google Scholar
• HashimotoKTamuraKBreakthrough breast cancer treatment – Parp inhibitor, BRCA, and triple negative breast cancerGan To Kagaku Ryoho20103711871191 [Japanese].20647696
   PubMedGoogle Scholar
• RatnamKLowJACurrent development of clinical inhibitors of poly(ADP-ribose) polymerase in oncologyClin Cancer Res2007131383138817332279
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med200936112313419553641
   PubMed Web of Science ®Google Scholar
• IsakoffSJOvermoyerBTungNMA phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancerJ Clin Oncol201028 abst 1019.
   Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• O‘ShaughnessyJSchwartzbergLSDansoMAA randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)J Clin Oncol201129 abst 1007.
   Web of Science ®Google Scholar
• DentRALindemanGJClemonsMSafety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trialJ Clin Oncol201028 abst 1018.
   Web of Science ®Google Scholar
• GelmonKDentRMackeyJRLaingKMcLeodDVermaSTargeting triple-negative breast cancer: optimising therapeutic outcomesAnn Oncol2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• TsutsuiSOhnoSMurakamiSHachitandaYOdaSPrognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancerBreast Cancer Res Treat200271677511859875
   PubMed Web of Science ®Google Scholar
• BaselgaJStemmerSPegoACetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trialCancer Res201070 abst PD01-01.
   Web of Science ®Google Scholar
• O’ShaughnessyJWecksteinDVukeljaSPreliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancerBreast Cancer Res Treat2007106S32 abst 308.
   Web of Science ®Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancerJ Clin Oncol200826 abst 1009.
   Web of Science ®Google Scholar
• FaivreSKroemerGRaymondECurrent development of mTOR inhibitors as anticancer agentsNat Rev Drug Discov20065867168816883305
   PubMed Web of Science ®Google Scholar
• HochgräfeFZhangLO’TooleSATyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cellsCancer Res2010709391940120861192
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJGintherCDasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitroBreast Cancer Res Treat2007105331932617268817
   PubMed Web of Science ®Google Scholar
• LacevicMMintonSSchmittMPhase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior antihormonal therapyBreast Cancer Res Treat2007106Suppl 1 abst 2097.
   Web of Science ®Google Scholar